Abstract:Abstract Background While circulating metabolites have been increasingly linked to cancer risk, the causality underlying these associations remains largely uninterrogated. Methods We conducted a comprehensive 2-sample Mendelian randomization (MR) study to evaluate the potential causal relationship between 913 plasma metabolites and the risk of seven cancers among European-ancestry individuals. Data on variant-metabolite associations were obtained from a genome-wide association study (GWAS) of plasma metabolites among 14,296 subjects. Data on variant-cancer associations were gathered from large-scale GWAS consortia for breast (N = 266,081), colorectal (N = 185,616), lung (N = 85,716), ovarian (N = 63,347), prostate (N = 140,306), renal cell (N = 31,190), and testicular germ cell (N = 28,135) cancers. MR analyses were performed with the inverse variance-weighted (IVW) method as the primary strategy to identify significant associations at Bonferroni-corrected P < 0.05 for each cancer type separately. Significant associations were subjected to additional scrutiny via weighted median MR, Egger regression, MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO), and reverse MR analyses. Replication analyses were performed using an independent dataset from a plasma metabolite GWAS including 8,129 participants of European ancestry. Results We identified 94 significant associations, suggesting putative causal associations between 66 distinct plasma metabolites and the risk of seven cancers. Remarkably, 68.2% (45) of these metabolites were each associated with the risk of a specific cancer. Among the 66 metabolites, O-methylcatechol sulfate and 4-vinylphenol sulfate demonstrated the most pronounced positive and negative associations with cancer risk, respectively. Genetically proxied plasma levels of these two metabolites were significantly associated with the risk of lung cancer and renal cell cancer, with an odds ratio and 95% confidence interval of 2.81 (2.33–3.37) and 0.49 (0.40–0.61), respectively. None of these 94 associations was biased by weak instruments, horizontal pleiotropy, or reverse causation. Further, 64 of these 94 were eligible for replication analyses, and 54 (84.4%) showed P < 0.05 with association patterns consistent with those shown in primary analyses. Conclusions Our study unveils plausible causal relationships between 66 plasma metabolites and cancer risk, expanding our understanding of the role of circulating metabolites in cancer genetics and etiology. These findings hold promise for enhancing cancer risk assessment and prevention strategies, meriting further exploration.

Plasma metabolomic profiles enhance precision medicine for volunteers of normal health

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Next generation plasma proteome profiling to monitor health and disease

Analysis of plasma metabolomes from 11 309 subjects in five population-based cohorts

Plasma metabolomic profiles predict near-term death among individuals with lower extremity peripheral arterial disease.

Plasma metabolomics profiles and breast cancer risk

Plasma Metabolic Fingerprints for Large-Scale Screening and Personalized Risk Stratification of Metabolic Syndrome

Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases

Human Plasma Metabolomics For Identifying Differential Metabolites And Predicting Molecular Subtypes Of Breast Cancer

Untargeted Metabolomic Analysis for the Clinical Screening of Inborn Errors of Metabolism

Breast Cancer Detection Using Targeted Plasma Metabolomics

Proteomic Profiling of Human Plasma for Cancer Biomarker Discovery

Utilization and Validation of Dried Blood Spot-Based Metabolomics in Plasma-Derived Diagnostic Models

Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk

Plasma Metabolites Forecast Occurrence and Prognosis for Patients With Diffuse Large B-Cell Lymphoma

Plasma Metabolites and Risk of Seven Cancers: a Two-Sample Mendelian Randomization Study among European Descendants

Plasma proteomic associations with genetics and health in the UK Biobank

Plasma Metabolomics for the Assessment of the Progression of Non-Small Cell Lung Cancer

Plasma Metabolic Profiling and Multiclass Diagnostic Model Development for Stable Angina Pectoris and Acute Myocardial Infarction

Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study

Mapping biological influences on the human plasma proteome beyond the genome